Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...

December 2, 2024

Developments

FDA accepts Revelation’s IND for Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...

December 2, 2024

Developments

Elite launches generic hydrocodone and acetaminophen tables for pain management

Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...

December 2, 2024

Developments

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...

December 2, 2024

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Developments

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...

November 27, 2024

Developments

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...

November 26, 2024

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Developments

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...

November 26, 2024

Developments

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...

November 25, 2024

Developments

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...

November 25, 2024

Developments

BioLineRx enters license agreement with Ayrmid for APHEXDA

BioLineRx (NASDAQ:BLRX; TASE:BLRX) and Ayrmid, the parent company of Gamida Cell, announced they have entered into a licensing agreement for motixafortide, commercially marketed in the U.S. as BioLineRx’s APHEXDA. The...

November 22, 2024

Developments

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

Rallybio (NASDAQ:RLYB) announced the commencement of an open-label Phase II trial of RLYB212 in pregnant women at high-risk of HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is...

November 22, 2024

Developments

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) announced positive topline results from the pivotal study designed to support its planned FDA PMA submission for approval to market its next-generation Perimeter B...

November 20, 2024

Developments

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS). The company states that NUZ-001 reduces the...

November 19, 2024

Developments

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Adverum Biotechnologies (NASDAQ:ADVM) announced topline 52-week results from its LUNA Phase 2 trial, new four-year long-term follow-up data from its OPTIC study, and key design elements for its pivotal program. Both the...

November 18, 2024

Developments

Therma Bright to spin off consumer product portfolio creating new company

Therma Bright (TSXV:THRM; QTCQB:TBRIF) announced plans to spin off its consumer product portfolio into a separate publicly traded company during the first half of 2025. The spin-off transaction will be subject to...

November 18, 2024

Developments

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...

November 15, 2024

Developments

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...

November 14, 2024

Developments

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...

November 13, 2024

Developments

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) announced positive clinical data from the fifth cohort of its RESOLVE Phase 1b/2a trial, a multi-center, open-label, dose-escalation study to evaluate the safety...

November 13, 2024

Developments

Lipella’s liposomal delivery platform granted patent by USPTO

Lipella Pharmaceuticals (NASDAQ:LIPO) announced that the U.S. Patent and Trademark Office (USPTO), has issued a patent for its proprietary liposomal delivery platform today. Lipella reports that the patent protects its...

November 12, 2024

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

FDA accepts Revelation’s IND for Gemini in CKD

Elite launches generic hydrocodone and acetaminophen tables for pain management

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

BioLineRx enters license agreement with Ayrmid for APHEXDA

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Therma Bright to spin off consumer product portfolio creating new company

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Lipella’s liposomal delivery platform granted patent by USPTO

General

More